CAS 25953-19-9|Cefazolin
| Common Name | Cefazolin | ||
|---|---|---|---|
| CAS Number | 25953-19-9 | Molecular Weight | 454.507 |
| Density | 2.0±0.1 g/cm3 | Boiling Point | / |
| Molecular Formula | C14H14N8O4S3 | Melting Point | 198-200ºC |
| MSDS | / | Flash Point | / |
Names
| Name | cefazolin |
|---|---|
| Synonym | More Synonyms |
Cefazolin BiologicalActivity
| Description | Cefazolin is an antibiotic used for the research of a number of anti-bacterial infections. Cefazolin can be used for the prophylaxis of surgical antimicrobial. Cefazolin has anti-inflammatory effect and can attenuate post-operative cognitive dysfunction (POCD)[1]. |
|---|---|
| Related Catalog | Research Areas >>InfectionResearch Areas >>Inflammation/ImmunologyResearch Areas >>Neurological DiseaseSignaling Pathways >>Anti-infection >>Bacterial |
| Target | Antibiotic[1] |
| In Vitro | Cefazolin (50-300 μg/mL; 6 or 24 hours) has a direct anti-inflammatory effect on C8-B4 cells stimulated by LPS (1 μg/mL)[1]. Cell Viability Assay[1] Cell Line: Mouse C8-B4 microglial cells Concentration: 50, 100, 150, 200, 250, and 300 μg/mL Incubation Time: 6 or 24 hours Result: Inhibited proinflammatory cytokine production. Inhibited IL-6 production at 50 and 100 μg/mL. |
| In Vivo | Cefazolin (300 mg/kg; injected intraperitoneally 1 h before surgery and then once per day for 5 days after surgery) can attenuate surgery-induced post-operative memory and learning impairment in mice. Cefazolin alone may induce cognitive dysfunction possibly by transient gut dysbiosis in mice without surgery[1]. Animal Model: Six- to 8-week-old CD-1 male mice (weighing 31-36 g) [1] Dosage: 300-500 mg/kg Administration: 10 mg in 0.1 mL was intraperitoneally injected 30 min before surgery and then once every day for 5 days. Result: Improved learning and memory after surgery and might impair learning and memory in mice without surgery. |
| References | [1]. Peng Liang, et al. Perioperative use of cefazolin ameliorates postoperative cognitive dysfunction but induces gut inflammation in mice. J Neuroinflammation. 2018 Aug 22;15(1):235. |
Chemical & Physical Properties
| Density | 2.0±0.1 g/cm3 |
|---|---|
| Melting Point | 198-200ºC |
| Molecular Formula | C14H14N8O4S3 |
| Molecular Weight | 454.507 |
| Exact Mass | 454.029999 |
| PSA | 234.93000 |
| LogP | 1.13 |
| Index of Refraction | 1.961 |
| InChIKey | MLYYVTUWGNIJIB-BXKDBHETSA-N |
| SMILES | Cc1nnc(SCC2=C(C(=O)O)N3C(=O)C(NC(=O)Cn4cnnn4)C3SC2)s1 |
Toxicological Information
CHEMICAL IDENTIFICATION |
ACUTE TOXICITY DATA - TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 3 gm/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- BYYADW Byoin Yakugaku. Hospital Pharmacology. (Yakuji Nippon Sha, 1-11 Izumi-cho, Kanda, Chiyoda-ku, Tokyo 101, Japan) V.1- 1975- Volume(issue)/page/year: 3,220,1978
- TYPE OF TEST :
- LD50 - Lethal dose, 50 percent kill
- ROUTE OF EXPOSURE :
- Intramuscular
- SPECIES OBSERVED :
- Rodent - mouse
- DOSE/DURATION :
- 4 gm/kg
- TOXIC EFFECTS :
- Details of toxic effects not reported other than lethal dose value
- REFERENCE :
- BYYADW Byoin Yakugaku. Hospital Pharmacology. (Yakuji Nippon Sha, 1-11 Izumi-cho, Kanda, Chiyoda-ku, Tokyo 101, Japan) V.1- 1975- Volume(issue)/page/year: 3,220,1978 ** OTHER MULTIPLE DOSE TOXICITY DATA **
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intraperitoneal
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 164 gm/kg/26W-I
- TOXIC EFFECTS :
- Blood - normocytic anemia Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol) Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - transaminases
- REFERENCE :
- NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 28(Suppl 7),1089,1980
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Rodent - rat
- DOSE/DURATION :
- 44100 mg/kg/35D-I
- TOXIC EFFECTS :
- Blood - changes in serum composition (e.g. TP, bilirubin, cholesterol) Biochemical - Enzyme inhibition, induction, or change in blood or tissue levels - transaminases Related to Chronic Data - death
- REFERENCE :
- NKRZAZ Chemotherapy (Tokyo). (Nippon Kagaku Ryoho Gakkai, 2-20-8 Kamiosaki, Shinagawa-Ku, Tokyo 141, Japan) V.1- 1953- Volume(issue)/page/year: 28(Suppl 7),1007,1980
- TYPE OF TEST :
- TDLo - Lowest published toxic dose
- ROUTE OF EXPOSURE :
- Intravenous
- SPECIES OBSERVED :
- Rodent - rabbit
- DOSE/DURATION :
- 11200 mg/kg/28D-I
- TOXIC EFFECTS :
- Kidney, Ureter, Bladder - changes in tubules (including acute renal failure, acute tubular necrosis)
- REFERENCE :
- BYYADW Byoin Yakugaku. Hospital Pharmacology. (Yakuji Nippon Sha, 1-11 Izumi-cho, Kanda, Chiyoda-ku, Tokyo 101, Japan) V.1- 1975- Volume(issue)/page/year: 3,220,1978 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOHS - National Occupational Hazard Survey (1974) NOHS Hazard Code - A1317 No. of Facilities: 33 (estimated) No. of Industries: 1 No. of Occupations: 1 No. of Employees: 528 (estimated) NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - A1317 No. of Facilities: 318 (estimated) No. of Industries: 1 No. of Occupations: 5 No. of Employees: 16111 (estimated) No. of Female Employees: 13596 (estimated)
Safety Information
| Hazard Codes | Xn |
|---|---|
| Risk Phrases | R20/21/22 |
| Safety Phrases | 26-36 |
| RIDADR | NONH for all modes of transport |
| HS Code | 3004909090 |
Customs
| HS Code | 3004909090 |
|---|
Articles48
More Articles| Isolation of Escherichia coli strains with AcrAB-TolC efflux pump-associated intermediate interpretation or resistance to fluoroquinolone, chloramphenicol and aminopenicillin from dogs admitted to a university veterinary hospital. J. Vet. Med. Sci. 76(7) , 937-45, (2014) Understanding the prevalence of antimicrobial-resistance and the relationship between emergence of resistant bacteria and clinical treatment can facilitate design of effective treatment strategies. We... | |
| Aspiration sclerotherapy combined with pasireotide to improve reduction of large symptomatic hepatic cysts (SCLEROCYST): study protocol for a randomized controlled trial. Trials 16 , 82, (2015) Aspiration sclerotherapy is an effective therapeutic option for large symptomatic hepatic cysts. However, incomplete cyst reduction following aspiration sclerotherapy is frequently reported. Strong po... | |
| Skeletal muscle and plasma concentrations of cefazolin during cardiac surgery in infants. J. Thorac. Cardiovasc. Surg. 148(6) , 2634-41, (2014) To describe the pharmacokinetics and tissue disposition of prophylactic cefazolin into skeletal muscle in a pediatric population undergoing cardiac surgery.The subjects included 12 children, with a me... |
Synonyms
| Cephazolin |
| 7-(1-(1H)-Tetrazolylacetamido)-3-[2-(5-methyl-1,3,4-thiadiazolyl)thiomethyl]-D3-cephem-4-carboxylic Acid |
| Cephamezine |
| 5-Thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[[(5-methyl-1,3,4-thiadiazol-2-yl)thio]methyl]-8-oxo-7-[[2-(1H-tetrazol-1-yl)acetyl]amino]-, (6R,7R)- |
| Cefazolinum |
| Cefazolina |
| Cephazoline |
| 5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid, 3-[[(5-methyl-1,3,4-thiadiazol-2-yl)thio]methyl]-8-oxo-7-[(1H-tetrazol-1-ylacetyl)amino]-, (6R,7R)- |
| (6R,7R)-3-[(5-methyl-1,3,4-thiadiazol-2-yl)sulfanylmethyl]-8-oxo-7-[[2-(tetrazol-1-yl)acetyl]amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
| Cefazoline |
| (6R,7R)-3-{[(5-Methyl-1,3,4-thiadiazol-2-yl)sulfanyl]methyl}-8-oxo-7-[(1H-tetrazol-1-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
| Cephazolidin |
| Ancef |
| MFCD00243010 |
| EINECS 247-362-8 |
| Cefazolin |
| (6R)-3-(5-methyl-[1,3,4]thiadiazol-2-ylsulfanylmethyl)-8-oxo-7t-(2-tetrazol-1-yl-acetylamino)-(6rH)-5-thia-1-aza-bicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
| (6R,7R)-3-{[(5-methyl-1,3,4-thiadiazol-2-yl)thio]methyl}-8-oxo-7-[(1H-tetrazol-1-ylacetyl)amino]-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid |
| Cefamezin |
| Cefazolin Acid |
